Therapeutic Response

17p deletion status confers therapeutic sensitivity to Ibrutinib in patients with Chronic Lymphocytic Leukemia.

Statements

Source and description
Imbruvica (ibrutinib) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to ibrutinib for the treatment of adult patients with chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL) with a 17p deletion.
Ibrutinib Therapy CLL / Waldenstroms Macroglobulinaemia. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved ibrutinib for reimbursement as a monotherapy, first-line treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are unsuitable for chemoimmunotherapy and whose tumors have 17p deletion or TP53 mutated disease.